GrowCo Capital

Cognition Therapeutics Expands Clinical Expertise

Joseph Lee — Thu, 04 Apr 2019 19:17:34 +0000

Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders caused by membrane trafficking dysfunction, today announced that Mary Sano, Ph.D. of Mount Sinai School of Medicine and Philip Scheltens, M.D., Ph.D. of the VU Medical Center (VUmc) Alzheimer’s Center in Amsterdam have accepted appointments to the Company’s Medical Advisory Board.

“Drs. Sano and Scheltens have shown a keen understanding and appreciation of our scientific approach and will provide valuable insights as we advance Elayta™ though the ongoing Phase 2 SPARC, SNAP and SHINE studies,” stated Chief Science Office Susan Catalano, Ph.D. “Their commitment to Cognition Therapeutics is an important validation of our scientific approach and speaks to the potential of our clinical programs.”

President and CEO Kenneth I. Moch added, “Ensuring access to a rich core of medical and scientific thought leaders is crucial as we evolve as a company. Drs. Sano’s and Scheltens’ unique perspective and deep experience in the research and development of innovative treatments for neurodegenerative disorders, combined with our in-house expertise, will be of great assistance as we chart the clinical development trajectory for Elayta.”

GrowCo Capital
817-769-6900
133 Nursery Lane
Fort Worth, Texas 76114

Site design by Teleos Marketing.

The post Cognition Therapeutics Expands Clinical Expertise appeared first on GrowCo Capital.

Cognition Therapeutics

Joseph Lee — Tue, 19 Feb 2019 16:05:14 +0000

Elayta Crossed Blood Brain Barrier and Reached CNS Levels Associated in Preclinical Studies with Cognitive Improvement

Pittsburgh, Feb. 19, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative disorders, announced today the publication of clinical data from the Company’s Phase 1 trial of Elayta™ (CT1812) in Alzheimer’s & Dementia: Translational Research & Clinical Interventions.

Top-line findings from this two-part randomized, double-blind, placebo-controlled Phase 1 study had previously been reported as part of a “Late Breaker” Oral Presentation at the 9th Annual Clinical Trials on Alzheimer’s Disease (CTAD) meeting. Results showed that Elayta was well tolerated by the 93 study participants, with mild headache and GI disturbances representing the most commonly observed adverse events. At peak plasma concentrations, dose-dependent increases in cerebrospinal fluid (CSF) levels of Elayta were measured, confirming that Elayta crossed the blood-brain barrier. No differences in plasma levels of Elayta were detected between cohorts of patients who were fed versus those who had fasted.

GrowCo Capital
817-769-6900
133 Nursery Lane
Fort Worth, Texas 76114

Site design by Teleos Marketing.

The post Cognition Therapeutics appeared first on GrowCo Capital.

Cognition Therapeutics: Undaunted Warrior in the Battle Against Alzheimer’s

Joseph Lee — Fri, 18 Jan 2019 19:08:57 +0000

While the “War on Cancer” has made significant progress, the “War on Alzheimer’s” has proven to be a seemingly implacable foe. The societal costs of neurodegenerative diseases are enormous – Alzheimer’s disease is the most common cognitive dementia, affecting one of every ten people over age 65 and nearly 35% over age 85. This translates into more than 5.4 million Alzheimer’s patients in the US alone, a number expected to reach 9 million by 2030 and 16 million by 2050 as the US population ages. Alzheimer’s is the sixth leading cause of death in the US and is the only leading cause of death currently without a way to prevent, cure or slow the disease (of the top 10 leading causes). As many as 25 million people worldwide are afflicted with less severe memory impairment known as mild cognitive impairment (MCI), which manifests several years before an actual clinical diagnosis of Alzheimer’s can be made. Patients suffering in the later stages of this disease require nearly full-time care; in the US alone, the economic burden of Alzheimer’s is currently estimated to be in excess of $110 billion annually.

GrowCo Capital
817-769-6900
133 Nursery Lane
Fort Worth, Texas 76114

Site design by Teleos Marketing.

The post Cognition Therapeutics: Undaunted Warrior in the Battle Against Alzheimer’s appeared first on GrowCo Capital.

The 360 Best Entrepreneurial Companies in America

Joseph Lee — Thu, 20 Dec 2018 23:37:26 +0000

For the past four years, Entrepreneur magazine has conducted a nationwide search to find the most entrepreneurial companies in the country, rating and ranking them using a proprietary algorithm that factors in their ability to expertly balance impact, innovation, growth, leadership and value. The results of this year’s search were our most impressive and diverse to date and can be found here: 2018 Entrepreneur 360™.

“Our annual evaluation of vetted data offers a 360-degree analysis of top privately-held companies across a multitude of industries,” explains Jason Feifer, editor in chief of Entrepreneur. “They are deemed successful not only by revenue numbers, but by how well-rounded they are. The companies that make the list have pushed boundaries with their innovative ideas, fostered strong company cultures, impacted their communities for the better, and increased their brand awareness.”

GrowCo Capital
817-769-6900
133 Nursery Lane
Fort Worth, Texas 76114

Site design by Teleos Marketing.

The post The 360 Best Entrepreneurial Companies in America appeared first on GrowCo Capital.

Cowtown Angels score big with $465 million sale of Encore Vision

Joseph Lee — Wed, 19 Dec 2018 19:42:36 +0000

Novartis has revealed how much it paid to buy Encore Vision, a Fort Worth startup that has developed an eyedrop to treat presbyopia — and it’s an eye-opener.

In an SEC filing Wednesday, the Swiss pharmaceutical giant that owns Alcon put the preliminary fair value of the transaction announced last month at $465 million. Novartis reported that the deal includes an initial cash payment of $375 million “before ordinary purcahse price adjustments,” plus $90 million due Encore shareholders over time “upon achievement of specified development and commercialization milestones.”

GrowCo Capital
817-769-6900
133 Nursery Lane
Fort Worth, Texas 76114

Site design by Teleos Marketing.

The post Cowtown Angels score big with $465 million sale of Encore Vision appeared first on GrowCo Capital.

Caregiving Benefits Expanding the Conversation Beyond Paid Leave

Joseph Lee — Wed, 05 Dec 2018 16:18:43 +0000

Employee Benefits News speaks to HR leaders and Benefits Specialists around the world on why it doesn’t matter what your workforce looks like, you have employee caregivers who need help. This article features Cariloop’s CEO, Michael Walsh, discussing the impact of caregiving in the workplace and expanding the conversation beyond just offering paid leave…

GrowCo Capital
817-769-6900
133 Nursery Lane
Fort Worth, Texas 76114

Site design by Teleos Marketing.

The post Caregiving Benefits Expanding the Conversation Beyond Paid Leave appeared first on GrowCo Capital.

Cognition Therapeutics Expands Industry

Joseph Lee — Tue, 27 Nov 2018 17:41:27 +0000

Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative disorders, today announced the addition of three renowned leaders in imaging and molecular biomarkers to the company’s Medical Advisory Board. The global thought leaders, Kaj Blennow, M.D., Ph.D. and Henrik Zetterberg, M.D. of the University of Gothenburg, Sweden and John Harrison, Ph.D. of the VU Medical Center (VUmc) Alzheimer’s Center in Amsterdam, add significant expertise in the research and development of biomarker tests and alternative endpoints to Cognition’s efforts in the development of its lead experimental medicine, Elayta™.

GrowCo Capital
817-769-6900
133 Nursery Lane
Fort Worth, Texas 76114

Site design by Teleos Marketing.

The post Cognition Therapeutics Expands Industry appeared first on GrowCo Capital.

Cognition Therapeutics Initiates Patient Dosing

Joseph Lee — Thu, 08 Nov 2018 17:21:33 +0000

Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced that patient treatment has begun in the Phase 2 SHINE study of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease. SHINE (Synaptic Health and Improvement of Neurological Function with Elayta) is a randomized, double-blind, placebo-controlled, parallel-group Phase 2 efficacy and safety study designed to enroll up to 160 adults with mild-to-moderate Alzheimer’s disease (MMSE 18-26).

GrowCo Capital
817-769-6900
1000 Forest Park Blvd., Suite 401
Fort Worth, TX 76110

The post Cognition Therapeutics Initiates Patient Dosing appeared first on GrowCo Capital.

Cognition Therapeutics to Sponsor Third International Sympsium on Sigma-2 Receptors

Joseph Lee — Wed, 24 Oct 2018 17:19:04 +0000

Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced its sponsorship of the Third International Symposium on Sigma-2 Receptors: Role in Health and Disease. The Symposium will be held in San Diego, California on November 3, 2018 beginning at 8:00 a.m. PT during Neuroscience 2018, the annual meeting of the Society for Neuroscience. The meeting is open to registered Neuroscience 2018 attendees.

GrowCo Capital
817-769-6900
133 Nursery Lane
Fort Worth, Texas 76114

Site design by Teleos Marketing.

The post Cognition Therapeutics to Sponsor Third International Sympsium on Sigma-2 Receptors appeared first on GrowCo Capital.

Cognition Therapeutics Receives $16.6 Million Multiyear NIA Grant

Joseph Lee — Tue, 02 Oct 2018 16:54:08 +0000

Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a multiyear grant expected to total $16.6 million to support the Phase 2 SHINE study of Elayta™ (CT1812).

SHINE (Synaptic Health and Improvement of Neurological Function with Elayta) is a randomized, double-blind, placebo-controlled, parallel-group Phase 2 safety and efficacy study expected to enroll up to 160 adults with mild-to-moderate Alzheimer’s disease (MMSE 18-26). Cognition expects to initiate patient dosing in the SHINE study during the fourth quarter of 2018. SHINE will be conducted in two parts. Part A will enroll 24 adults who will receive Elayta at doses of 100 or 300 mg per day or placebo for 6 months. Part B will be initiated pending the successful completion of Part A and will randomize up to 134 additional individuals into the study with the same design and duration.

GrowCo Capital
817-769-6900
133 Nursery Lane
Fort Worth, Texas 76114

Site design by Teleos Marketing.

The post Cognition Therapeutics Receives $16.6 Million Multiyear NIA Grant appeared first on GrowCo Capital.